Literature DB >> 11686492

Role of bradykinin B2 receptors in the formation of vasogenic brain edema in rats.

N Plesnila1, J Schulz, M Stoffel, J Eriskat, D Pruneau, A Baethmann.   

Abstract

Bradykinin is a mediator of brain edema acting through B2 receptors. However, it is not known if bradykinin mediates the formation of cytotoxic or vasogenic brain swelling. To investigate this question we subjected rats to a cryogenic brain lesion over the left parietal cortex, a model well known to produce predominantly vasogenic brain edema. We inhibited bradykinin B2 receptors with the recently characterized nonpeptide B2 receptor antagonist, LF 16-0687. The animals were assigned to three groups (n = 10, each) receiving 10, or 100 microg/kg/min LF 16-0687 or vehicle (0.9% NaCl). Treatment started 15 min before trauma and was continued for 24 h. Another three groups of animals (n = 10, each) received 10 microg/kg/min LF 16-0687 starting 30 or 60 min after trauma or vehicle (0.9% NaCl) for 24 h. Animals were then sacrificed and swelling and water content of the brain were determined. In the vehicle treated group the traumatized hemisphere swelled by 9.3 +/- 1.1% as compared to the untraumatized contralateral side. Pretreatment with 10 microg/kg/min LF 16-0687 decreased brain swelling significantly to 6.4 +/- 1.3% (p < 0.05). Pre-treatment with 100 microg/kg/min was found to be less effective and did not result in a significant reduction of brain swelling (7.4 + 1.3%). Treatment with LF 16-0687 for 24 h (10 microg/kg/min) started 30 or 60 min after trauma did not reduce brain water content or hemispheric swelling. These results demonstrate that brain injury-mediated bradykinin production induces vasogenic brain edema by B2 receptor stimulation. Our findings further clarify the role of bradykinin in the pathophysiology of brain edema formation and confirm the therapeutic potency of bradykinin B2 receptor inhibition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11686492     DOI: 10.1089/08977150152693746

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  13 in total

1.  HOE-140, an antagonist of B2 receptor, protects against memory deficits and brain damage induced by moderate lateral fluid percussion injury in mice.

Authors:  Ana Paula Oliveira Ferreira; Fernanda Silva Rodrigues; Iuri Domingues Della-Pace; Bibiana Castagna Mota; Sara Marchesan Oliveira; Camila de Campos Velho Gewehr; Franciane Bobinski; Clarissa Vasconcelos de Oliveira; Juliana Sperotto Brum; Mauro Schneider Oliveira; Ana Flavia Furian; Claudio Severo Lombardo de Barros; Adair Roberto Soares dos Santos; Juliano Ferreira; Michele Rechia Fighera; Luiz Fernando Freire Royes
Journal:  Psychopharmacology (Berl)       Date:  2013-11-08       Impact factor: 4.530

Review 2.  Involvement of bradykinin in brain edema development after ischemic stroke.

Authors:  Marina Dobrivojević; Katarina Špiranec; Aleksandra Sinđić
Journal:  Pflugers Arch       Date:  2014-04-23       Impact factor: 3.657

Review 3.  Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury.

Authors:  Dan Shlosberg; Mony Benifla; Daniela Kaufer; Alon Friedman
Journal:  Nat Rev Neurol       Date:  2010-06-15       Impact factor: 42.937

4.  Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammation.

Authors:  Furat Raslan; Tobias Schwarz; Sven G Meuth; Madeleine Austinat; Michael Bader; Thomas Renné; Klaus Roosen; Guido Stoll; Anna-Leena Sirén; Christoph Kleinschnitz
Journal:  J Cereb Blood Flow Metab       Date:  2010-03-03       Impact factor: 6.200

5.  The role of bradykinin B(1) and B(2) receptors for secondary brain damage after traumatic brain injury in mice.

Authors:  Raimund Trabold; Christian Erös; Klaus Zweckberger; Jane Relton; Heike Beck; Juerg Nussberger; Werner Müller-Esterl; Michael Bader; Eric Whalley; Nikolaus Plesnila
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-23       Impact factor: 6.200

6.  LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces ischemic brain injury in a murine model of transient focal cerebral ischemia.

Authors:  Li Ding-Zhou; Isabelle Margaill; Bruno Palmier; Didier Pruneau; Michel Plotkine; Catherine Marchand-Verrecchia
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

Review 7.  Plasma kallikrein-kinin system and diabetic retinopathy.

Authors:  Jia Liu; Edward P Feener
Journal:  Biol Chem       Date:  2013-03       Impact factor: 3.915

Review 8.  Role of the kallikrein-kinin system in traumatic brain injury.

Authors:  Christiane Albert-Weissenberger; Stine Mencl; Sarah Hopp; Christoph Kleinschnitz; Anna-Leena Sirén
Journal:  Front Cell Neurosci       Date:  2014-11-03       Impact factor: 5.505

9.  Enhancement of bradykinin-induced relaxation by focal brain ischemia in the rat middle cerebral artery: Receptor expression upregulation and activation of multiple pathways.

Authors:  Youhai Li; Natalia Lapina; Nina Weinzierl; Lothar Schilling
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240

10.  Blocking of bradykinin receptor B1 protects from focal closed head injury in mice by reducing axonal damage and astroglia activation.

Authors:  Christiane Albert-Weissenberger; Christian Stetter; Sven G Meuth; Kerstin Göbel; Michael Bader; Anna-Leena Sirén; Christoph Kleinschnitz
Journal:  J Cereb Blood Flow Metab       Date:  2012-05-09       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.